Clinical trials
for patients
Learn about available clinical trials
-
March 31, 2025Pamplona/MadridIn recruitment
LOXO-BTK-20030 Clinical trial of pyrtobrutinib (LOXO-305) compared to ibrutinib in patients with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (BRUIN-CLL-314).
The objectives of this clinical trial are as follows: - To determine the response of CLL/LLCP patients to treatment with pyrtobrutinib (group A) compared to ibrutinib (group B). - Determine the duration of beneficial effects of treatment with the study drugs (including how long patients live). - Determine safety and tolerability in group A and group B. - Determine how patients in group A are doing compared to those in group B. -
March 31, 2025PamplonaIn recruitment
RMC-6236-302 Phase III, multicenter, open-label, randomized, open-label clinical trial to evaluate RMC-6236 in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDCA).
The purpose of a trial is to collect information about the investigational drug: RMC-6236 -
March 31, 2025Pamplona/MadridIn recruitment
J2N-MC-JZNX Phase II clinical trial to evaluate the efficacy and safety of Pirtobrutinib in participants with leukemia who have previously received treatment with a covalent Bruton's tyrosine kinase inhibitor.
Clinical trial to compare the overall response rate of: - pirtobrutinib 200 mg vs. 120 mg - pirtobrutinib 200 mg vs. 60 mg -
March 31, 2025PamplonaIn recruitmentEarly phase
81201887MDG3002 Trial for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in primary clinical studies.
The objective of this study is to monitor the safety and occurrence of drug effects over a longer time by following the study patients for 42 months. -
March 26, 2025Pamplona/MadridIn recruitment
Diabet2Predict Project of Genetic Prediction and Nutritional Intervention with Postbiotics modulators of the microbiota in patients with Type 2 diabetes.
The main objective of the project is to evaluate the effect of postbiotic administration on glycemic control, insulin resistance and microbiota composition in subjects with type 2 diabetes (DM2). -
March 25, 2025Pamplona/MadridIn recruitmentEarly phase
-
March 25, 2025Pamplona/MadridIn recruitment
GRWD5769-ST-01 ERAP-1-mediated immunopeptidome-targeted trial
The main objective of this clinical trial is to determine the safety and efficacy of the study drug 12GRWD5769, alone or in combination with another drug called Libtayo® (cemiplimab), against advanced or metastatic malignant solid tumors. -
March 20, 2025Pamplona/MadridIn recruitment
D7630C00001 Datopotamab Deruxtecan (Dato- DXd) trial in patients with inoperable locally recurrent inoperable or metastatic PD-L1-positive triple-negative breast cancer
In this trial, we will compare the investigational treatment with the reference chemotherapy (either paclitaxel, nab-paclitaxel or gemcitabine carboplatin) in combination with pembrolizumab. This trial will also help us to better understand the disease being studied and the health problems associated with it. -
March 20, 2025Pamplona/MadridIn recruitment
MK-3543-007 Clinical trial to evaluate the efficacy and safety of Bomedemstat compared to hydroxycarbamide in essential thrombocythemia.
The main objective is to compare bomedemstat with hydroxycarbamide in terms of RCHD. Hypothesis (H1): Bomedemstat is superior to hydroxycarbamide in terms of RCHD. -
March 20, 2025PamplonaIn recruitment
GR40549 Trial to evaluate the long-term safety and tolerability of the port delivery system device with ranibizumab in patients with neovascular age-related macular degeneration
The purpose of this study is to evaluate the long-term effects, good or bad, of the ocular implant (in the eye) in you and your wet AMD, whereby a dose of ranibizumab is administered. The ocular implant delivers ranibizumab continuously (without interruption) over an extended period of time into the back of the eye and can be recharged by the study doctor. Since the implant releases ranibizumab over time, you may not need treatment as often. The intention is to keep the implant in the eye perman...